Recombinant human alkaline phosphatase - AMRIF/CEVEC

Drug Profile

Recombinant human alkaline phosphatase - AMRIF/CEVEC

Alternative Names: hRESCAP; Recombinant human placental alkaline phosphatase; rhuAP; rhuAP-CAP cell; Theraptech project

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alloksys Life Sciences; CEVEC Pharmaceuticals
  • Developer AMRIF; CEVEC Pharmaceuticals
  • Class Phosphoric monoester hydrolases; Recombinant proteins
  • Mechanism of Action Cytokine modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in Netherlands (Parenteral)
  • 13 Jan 2014 Recombinant human alkaline phosphatase - AMRIF/CEVEC is available for licensing.
  • 23 Oct 2013 AMRIF completes phase I trials in Rheumatoid arthritis (NCT01889147)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top